Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 5
1967 2
1968 6
1969 3
1970 6
1971 10
1972 7
1973 8
1974 7
1975 10
1976 18
1977 23
1978 10
1979 14
1980 12
1981 13
1982 11
1983 9
1984 9
1985 8
1986 11
1987 12
1988 11
1989 8
1990 12
1991 13
1992 5
1993 5
1994 14
1995 10
1996 12
1997 13
1998 9
1999 11
2000 19
2001 11
2002 21
2003 31
2004 22
2005 31
2006 28
2007 22
2008 28
2009 40
2010 46
2011 29
2012 36
2013 59
2014 61
2015 58
2016 51
2017 49
2018 39
2019 32
2020 37
2021 35
2022 31
2023 18
2024 35
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,100 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, Pyne S, Ridd MJ, Francis N, Soulsby I, Thomas K, Permyakova N, Little P, Muller I, Nuttall J, Griffiths G, Thomas KS, Layton AM; SAFA trial investigators. Santer M, et al. BMJ. 2023 May 16;381:e074349. doi: 10.1136/bmj-2022-074349. BMJ. 2023. PMID: 37192767 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomly assigned (1:1) to either 50 mg/day spironolactone or matched placebo until week six, increasing to 100 mg/day spironolactone or placebo until week 24. ...Spironolactone is a useful alternative to oral antibiotics for …
INTERVENTIONS: Participants were randomly assigned (1:1) to either 50 mg/day spironolactone or matched placebo until week six, increa …
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, McNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E; National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Butler J, et al. JAMA Cardiol. 2017 Sep 1;2(9):950-958. doi: 10.1001/jamacardio.2017.2198. JAMA Cardiol. 2017. PMID: 28700781 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone. ...INTERVENTIONS: High-dose spironolactone (100 mg) vs placebo or 25 mg spironolactone ( …
OBJECTIVE: To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) l …
Spironolactone for heart failure with preserved ejection fraction.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Pitt B, et al. N Engl J Med. 2014 Apr 10;370(15):1383-92. doi: 10.1056/NEJMoa1313731. N Engl J Med. 2014. PMID: 24716680 Free article. Clinical Trial.
BACKGROUND: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fr …
BACKGROUND: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejec …
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Pitt B, et al. N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001. N Engl J Med. 1999. PMID: 10471456 Free article. Clinical Trial.
A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. RESULTS: The trial was discontinued early, after a mean follow-up period of 24 months, because an interim a …
A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end …
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S; BARACK-D Investigators; BARACK-D Investigators; Regional coordinating centre teams. Hobbs FDR, et al. Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30. Nat Med. 2024. PMID: 39349629 Free PMC article. Clinical Trial.
Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecified safety stop criteria. ...Spironolactone should not be used for people with stage 3b CKD without another explicit treatment indicati …
Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecifie …
Eplerenone in patients with systolic heart failure and mild symptoms.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Zannad F, et al. N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14. N Engl J Med. 2011. PMID: 21073363 Free article. Clinical Trial.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Pitt B, et al. N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31. N Engl J Med. 2003. PMID: 12668699 Free article. Clinical Trial.
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. Filippatos G, et al. Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29. Eur Heart J. 2016. PMID: 27130705 Free PMC article. Clinical Trial.
Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT.
Santer M, Lawrence M, Pyne S, Renz S, Stuart BL, Sach T, Ridd M, Thomas KS, Nuttall J, Permyakova N, Eminton Z, Francis N, Little P, Muller I, Soulsby I, Thomas K, Griffiths G, Layton AM. Santer M, et al. Health Technol Assess. 2024 Sep;28(56):1-86. doi: 10.3310/MYJT6804. Health Technol Assess. 2024. PMID: 39268864 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomised 1 : 1, using an independent web-based procedure, to either 50 mg/day spironolactone or matched placebo until week 6, increasing to 100 mg/day spironolactone or matched placebo until week 24. ...Mean scores at week 12 were …
INTERVENTIONS: Participants were randomised 1 : 1, using an independent web-based procedure, to either 50 mg/day spironolactone or ma …
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics.
Kosiborod MN, Cherney D, Connelly K, Desai AS, Guimarães PO, Kuthi L, Lala A, Madrini V Jr, Merkely B, Villota JN, Squire I, Testani JM, Vaclavik J, Verma S, Wranicz J, Dahl M, Eudicone JM, Friberg L, Petrie MC. Kosiborod MN, et al. JACC Heart Fail. 2024 Oct;12(10):1707-1716. doi: 10.1016/j.jchf.2024.05.003. Epub 2024 May 13. JACC Heart Fail. 2024. PMID: 38878009 Free article. Clinical Trial.
Participants achieving normokalemia while on spironolactone 25 mg daily were randomized to continuing SZC or matching placebo for 6 months. ...(Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients with Symptomatic HFrEF Receiving S …
Participants achieving normokalemia while on spironolactone 25 mg daily were randomized to continuing SZC or matching placebo for 6 m …
1,100 results